1. Home
  2. IMMR vs ABOS Comparison

IMMR vs ABOS Comparison

Compare IMMR & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immersion Corporation

IMMR

Immersion Corporation

HOLD

Current Price

$6.28

Market Cap

207.5M

Sector

Technology

ML Signal

HOLD

Logo Acumen Pharmaceuticals Inc.

ABOS

Acumen Pharmaceuticals Inc.

HOLD

Current Price

$2.52

Market Cap

182.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMMR
ABOS
Founded
1993
1996
Country
United States
United States
Employees
8
N/A
Industry
Computer peripheral equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
207.5M
182.0M
IPO Year
1999
2021

Fundamental Metrics

Financial Performance
Metric
IMMR
ABOS
Price
$6.28
$2.52
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$13.50
$8.00
AVG Volume (30 Days)
461.6K
292.3K
Earning Date
04-13-2026
05-12-2026
Dividend Yield
5.11%
N/A
EPS Growth
N/A
N/A
EPS
0.02
N/A
Revenue
$35,013,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$303.75
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.25
$0.99
52 Week High
$8.15
$3.60

Technical Indicators

Market Signals
Indicator
IMMR
ABOS
Relative Strength Index (RSI) 52.74 51.64
Support Level $5.78 $2.24
Resistance Level $6.39 $2.77
Average True Range (ATR) 0.24 0.14
MACD -0.03 0.01
Stochastic Oscillator 44.01 66.41

Price Performance

Historical Comparison
IMMR
ABOS

About IMMR Immersion Corporation

Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.

About ABOS Acumen Pharmaceuticals Inc.

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.

Share on Social Networks: